Kwality Pharmaceuticals Ltd

₹ 984 -0.46%

11 Jun 1:56 p.m.

About

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products^[1]

Key Points

Business Overview:^[1]^[2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations

Website BSE

Market Cap ₹ 1,021 Cr.
Current Price ₹ 984
High / Low ₹ 1,070 / 481
Stock P/E 25.6
Book Value ₹ 256
Dividend Yield 0.00 %
ROCE 18.3 %
ROE 16.2 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 15.5%
Company's median sales growth is 22.4% of last 10 years

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has high debtors of 154 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	64	70	56	56	69	67	70	78	92	80	90	84	116
	48	52	40	41	57	54	54	61	71	63	70	67	90
Operating Profit	16	18	16	15	12	14	15	17	21	17	20	18	26
OPM %	25%	26%	28%	27%	17%	20%	22%	21%	23%	22%	22%	21%	22%
	2	0	1	0	-15	0	0	1	-7	0	0	1	1
Interest	1	1	1	2	2	2	2	3	3	2	3	2	2
Depreciation	3	3	4	4	4	5	5	5	5	4	5	5	5
Profit before tax	14	14	11	10	-10	7	8	10	6	11	13	11	19
Tax %	25%	25%	20%	28%	-24%	25%	24%	21%	28%	25%	33%	25%	24%
	11	11	9	7	-7	5	6	8	4	8	8	9	14
EPS in Rs	10.13	10.17	8.72	6.97	-7.09	5.25	6.03	7.42	4.34	8.07	8.18	8.23	13.97
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	60	52	76	95	137	165	138	261	456	251	307	370
	56	49	70	86	125	149	124	231	284	190	241	290
Operating Profit	4	4	6	9	12	15	14	29	172	61	67	80
OPM %	6%	7%	8%	9%	8%	9%	10%	11%	38%	24%	22%	22%
	0	1	0	2	1	1	4	2	4	-14	-5	2
Interest	1	1	1	2	2	2	3	3	3	7	10	10
Depreciation	1	1	2	2	3	3	4	6	11	15	20	18
Profit before tax	2	2	3	6	8	11	11	22	162	26	31	54
Tax %	47%	29%	39%	41%	38%	31%	24%	29%	26%	24%	24%	26%
	1	1	2	3	5	8	8	15	120	19	24	40
EPS in Rs	0.95	1.32	1.89	3.31	4.51	7.28	8.12	14.86	115.70	18.76	23.11	38.44
Dividend Payout %	0%	0%	0%	9%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	22%
5 Years:	22%
3 Years:	-7%
TTM:	21%

Compounded Profit Growth
10 Years:	41%
5 Years:	37%
3 Years:	-31%
TTM:	36%

Stock Price CAGR
10 Years:	%
5 Years:	95%
3 Years:	37%
1 Year:	85%

Return on Equity
10 Years:	27%
5 Years:	28%
3 Years:	15%
Last Year:	16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4	4	5	5	10	10	10	10	10	10	10	10
Reserves	13	15	18	21	21	28	37	52	172	192	216	255
	6	8	13	19	26	28	35	41	54	90	98	112
	12	10	17	27	41	40	53	65	106	71	74	72
Total Liabilities	35	38	52	72	98	107	135	169	343	364	398	451
	11	11	11	16	19	28	42	56	91	120	138	144
CWIP	0	0	0	0	0	0	0	3	12	14	0	0
Investments	3	4	5	7	9	8	8	9	4	4	4	4
	21	23	36	50	70	71	86	102	236	226	256	303
Total Assets	35	38	52	72	98	107	135	169	343	364	398	451

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	-0	1	-3	4	-0	12	6	26	59	42	43	53
	-4	-1	-2	-7	-6	-11	-17	-23	-63	-48	-26	-28
	3	1	5	5	5	-2	12	1	6	1	-17	-14
Net Cash Flow	-2	0	0	1	-1	-1	1	4	2	-5	-0	10

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	41	63	95	87	99	86	80	53	57	107	138	154
Inventory Days	58	61	54	72	54	34	94	38	97	310	187	167
Days Payable	58	40	61	67	79	52	96	58	63	117	106	112
Cash Conversion Cycle	41	85	89	92	74	68	78	33	91	300	219	209
Working Capital Days	60	81	87	79	76	62	99	48	89	212	196	196
ROCE %	12%	11%	15%	19%	19%	21%	18%	26%	97%	18%	16%	18%

Shareholding Pattern

Numbers in percentages

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
	54.45%	54.44%	54.44%	54.73%	54.73%	54.76%	54.76%	54.82%	54.82%	54.82%	54.82%	54.82%
	0.00%	0.00%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%	0.02%	0.03%	0.32%
	45.55%	45.56%	45.54%	45.25%	45.25%	45.22%	45.22%	45.17%	45.18%	45.15%	45.14%	44.86%
No. of Shareholders	1,049	4,198	5,376	6,211	6,943	6,291	5,786	5,695	5,273	7,487	8,947	9,420

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	50.14%	50.14%	50.14%	51.52%	54.13%	54.43%	54.73%	54.82%	54.82%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%	0.32%
	49.86%	49.86%	49.86%	48.48%	45.87%	45.57%	45.25%	45.17%	44.86%
No. of Shareholders	147	198	180	157	148	581	6,211	5,695	9,420

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

DRHP

Credit ratings

Concalls

Jun 2025

Transcript

Notes
PPT
May 2024

Transcript

Notes
PPT
May 2024

Transcript

Notes
PPT
Aug 2023

Transcript

Notes
PPT
May 2022

Transcript

Notes
PPT